PTGS2 and diabetic neuropathy: NF-kB inhibition reduces pro-inflammatory mediators such as cyclooxygenase-2 (COX-2), TNF-α, and interleukin-6 (IL-6), while also decreasing oxidative damage markers such as MDA, further highlighting the neuroprotective potential of AMPK enhancers against diabetic neuropathy.